Is MMTec, Inc. (MTC) a Buy, Sell, or Hold?
MMTec, Inc.
NASDAQ:MTC
$2.56 USD
$0.01 (0.39%)
- Volume
- 13.71K
- Average Volume
- 102.74K
- Market Capitalization
- $64.48M
- P/E Ratio
- -1.23
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.10
- Year Low
- $0.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.50
| Source | Headline |
|---|---|
|
Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform
BILLERICA, Mass.--(BUSINESS WIRE)--Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics”, in the "Breakthrough" special issue of Lab on a Chip. The study details a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic (PK) profiles of small-molecule drugs. The research marks a significant demonstration of how combinatorial NAMs en. businesswire.com - 2026-06-23 13:49:00 |
|
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in w gurufocus.com - 2026-06-07 12:00:00 |
|
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demo gurufocus.com - 2026-06-06 15:00:00 |
